Shareholders expected to receive approximately $0.12 per share in cash upon closing of transaction and up to approximately $0.14 per CVR under revised terms Further Adjourns Special Meeting to October 3, 2025 SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , Sept.
Adjournment to provide time for continued discussions regarding possible revised financial terms of transaction with XenoTherapeutics SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , Sept.
SOUTH SAN FRANCISCO, Calif and VANCOUVER, BC , Aug. 25, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) announced on August 14, 2025 that, in connection with the Company's previously announced return of capital distribution in the aggregate amount of US$80,000,000 (the "Distribution") to the holders of common shares of the Company ("Common Shares" and the holders...
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , Aug. 14, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) today announced that, in connection with the Company's recently announced return of capital distribution in the aggregate amount of US$80,000,000 (the "Distribution") to the holders of common shares of the Company ("Common Shares" and the holders of such Commo...
SOUTH SAN FRANCISCO, Calif and VANCOUVER, Canada , Aug. 6, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) today announced that, following the Company's receipt of an order from the Supreme Court of British Columbia (the "Court") on August 5, 2025, authorizing a reduction in the capital of the common shares of the Company (the "Common Shares" and the holders of s...
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , July 23, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) today announced that, in connection with its previously announced business combination agreement with XenoTherapeutics, Inc. ("Xeno"), a non-profit biotechnology company, under which Xeno will acquire (the "Transaction") all of the issued and outstanding commo...
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of ESSA Pharma Inc. (NASDAQ: EPIX) to XenoTherapeutics, Inc. is fair to ESSA shareholders. Halper Sadeh encourages ESSA shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zha...
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC and BOSTON and EMERYVILLE, Calif.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.